U.S. patent attorney

Shana K. Cyr

Intricacies of the 30-Month Stay in Pharmaceutical Patent Cases
Sunday, March 25, 2018
Pharmaceutical patent litigations between branded and generic drug companies often take place before the generic drug is marketed. read more
Dead Zone: Are Your Biological Products Ready for FDA’s Regulatory Transition?
Sunday, April 30, 2017
On March 23, 2020, hundreds of approved and pending applications for biological products will face a regulatory transition as the U.S. Food and Drug Administration (FDA) implements the “deemed to be a license” provision of ... read more